The Fine Print Behind “Breakthrough” Alzheimer’s Drugs

Why I’m Writing About This?

I came across a paid article on Substack this week titled Pharma’s Influence on the FDA. I did not subscribe, partly because I already have enough subscriptions quietly nibbling at my bank account like highly educated mice, and partly because the subject itself is bigger than one article.

But the title stopped me.

Because if you are living anywhere near Alzheimer’s, dementia, early diagnosis, biomarker testing, infusion drugs, clinical trials, or the exhausting emotional weather system that surrounds all of it, the relationship between pharmaceutical companies and the FDA is not an abstract policy debate.

It is personal.

It sits inside the questions families are being asked to answer.

Should we pursue this drug?

What does approval really mean?

How much benefit is proven?

What are the risks?

Who paid for the research?

Who reviewed the evidence?

Who gets to call something “meaningful”?

And who benefits when desperate families are told there is finally hope?

I am not anti-pharma. That would be foolish. Modern medicine has given us extraordinary treatments, and many people are alive today because pharmaceutical research worked. I am also not anti-FDA. The agency has an almost impossible job, standing between public safety, political pressure, scientific uncertainty, industry urgency, and patients who do not have the luxury of waiting forever.

But I am deeply wary of the phrase “nothing to see here.”

Nothing to see here is what powerful systems say when the public starts looking too closely.

Nothing to see here is what gets said when conflicts are technically disclosed but not truly understood.

Nothing to see here is what families hear when they ask perfectly reasonable questions and are made to feel difficult, emotional, or uninformed.

And in Alzheimer’s, where fear and hope are already pressed so tightly together they can barely breathe, “nothing to see here” is simply not good enough.

We need better than blind trust.

We need better than blanket suspicion.

We need transparency, humility, and plain English.

Because approval is not the same thing as certainty. Biomarker change is not the same thing as restored life. Hope is not the same thing as proof. And families deserve to know where the evidence is strong, where it is still evolving, and where commercial pressure may be standing just a little too close to the microphone.

So this is not a conspiracy piece.

It is a trust piece.

And trust, once it starts leaking, is very hard to patch with press releases.